Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: A randomized study
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background and Objectives: Clozapine is considered to be particularly effective in the treatment of dually diagnosed (DD) patients with psychosis and substance use disorders. However, its use is restricted by potentially severe side effects. The aim of the present pilot study was to compare the effects of clozapine with the newer second generation antipsychotic (SGA) ziprasidone in DD‐patients. Methods: Thirty (n = 30) patients with schizophrenia and cannabis abuse/dependence were randomized to ziprasidone or clozapine and were followed up for up to 12 months. Results: Cannabis use was reduced in both groups during follow‐up. Clozapine treatment was associated with less positive symptoms of schizophrenia, more side effects and poorer compliance with treatment. Conclusions: Results from this small pilot RCT suggest beneficial effects of both clozapine and ziprasidone in the treatment of cannabis use disorders in psychotic patients. Larger‐scale RCTs are needed in order to assess advantages and disadvantages of the different SGAs in dually diagnosed populations. (Am J Addict 2014;23:308–312)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.
Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis, G. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61162-3 · Cited by 2,224 · cited 1×
“Cannabis use is associatedwith negative impact on long‐term rehabilitation results in patients with schizophrenia.(1) Concerning pharmacologic treatment strategies for patients with schizophrenia and comorbid substance use disorders (Dual Diagnosis1⁄4DD patients), first generation antipsychotic medications (FGA) may h…”
BackgroundLingjærde, O., Ahlfors, U. G., Bech, P., Dencker, S. J., & Elgen, K. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb10566.x · Cited by 1,705
Treatment of Dual Diagnosis Disorders
Murthy, P., & Chand, P. (2012) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328351a3e0 · Cited by 115
Cited by
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Pharmacotherapies for cannabis dependence.
Marshall, K., Gowing, L., Ali, R., & Le Foll, B. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008940.pub2 · Cited by 156
Pharmacotherapies for cannabis dependence
Nielsen, S., Gowing, L., Sabioni, P., & Le Foll, B. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008940.pub3 · Cited by 96
Krause, M., Huhn, M., Schneider-Thoma, J., Bighelli, I., Gutsmiedl, K., & Leucht, S. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.11.1105 · Cited by 86
Rafizadeh, R., Danilewitz, M., Bousman, C. A., Mathew, N., White, R. F., Bahji, A., Honer, W. G., & Schütz, C. G. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811221142575 · Cited by 41
“The second RCT (n = 30) showed no difference between clozapine-treated versus ziprasidone-treated individuals after 12 months of follow-up with high dropout rates (Schnell et al., 2014).”
Background
Metadata
- Authors
- Schnell, T., Koethe, D., Krasnianski, A., Gairing, S., Schnell, K., Daumann, J., & Gouzoulis‐Mayfrank, E.
- Venue
- The American Journal on Addictions
- Publisher
- Wiley
- Published
- 2014-03-15
- Volume
- 23
- Issue
- 3
- Pages
- 308-312
- ISSN
- 1055-0496 (ISSN-L)
- 1521-0391
- OpenAlex
- W1910190157
- Cited by
- 46
- References
- 3
- FWCI
- 4.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: A randomized study. https://app.cochat.ai/papers/10.1111/j.1521-0391.2014.12126.x
- The paper
- Schnell, T., Koethe, D., Krasnianski, A., Gairing, S., Schnell, K., Daumann, J., & Gouzoulis‐Mayfrank, E. (2014). Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: A randomized study. The American Journal on Addictions. https://doi.org/10.1111/j.1521-0391.2014.12126.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.